Pursuing unexplored targets to halt and reverse fibrotic activity in the clinic
Mediar is pioneering a novel approach to fibrosis treatment that disables the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure.
Go back to Portfolio Page